Why it matters: This article highlights the shift in drug testing priorities from cannabis to fentanyl. The supplier of drug testing kits, Psychemedics, has introduced an updated screening panel that prioritizes testing for fentanyl due to the changing legislative landscape and increasing rates of fentanyl overdose.
What they are saying: Psychemedics argues that traditional drug tests are outdated and do not address the needs of employers or employees. The company believes that current tests are not effective in detecting fentanyl compared to traditional opioids. Psychemedics claims that their hair-based drug tests are more accurate in detecting other drugs besides cannabis, including opioids, cocaine, and amphetamines.
The big picture: Psychemedics’ new drug screening panels aim to address the evolving perception of risks associated with cannabis use versus the harms and risks associated with fentanyl. The company believes that their updated testing method provides a more accurate reading than urine testing without unfairly targeting cannabis users. The FDA has reportedly approved this updated form of testing.
What to watch: It will be interesting to see if other drug testing companies follow suit and prioritize testing for fentanyl over cannabis in response to the changing legislative landscape and public perception. Additionally, the impact of these updated drug tests on workplace policies and employee protections for cannabis use should be monitored.
My take: This article highlights the need for drug testing practices to adapt to the changing landscape of drug use and legislation. Psychemedics’ prioritization of fentanyl testing reflects the increasing concern over the opioid crisis. While it may be a step forward for cannabis users, it also raises questions about the fairness of drug testing and the potential stigma associated with cannabis use. It remains to be seen how these updated drug tests will be received and adopted by employers and employees.
